Literature DB >> 7774329

Immune responses to Aspergillus fumigatus and Pseudomonas aeruginosa antigens in cystic fibrosis and allergic bronchopulmonary aspergillosis.

P S Murali1, K Pathial, R H Saff, M L Splaingard, D Atluru, V P Kurup, J N Fink.   

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) in Cystic Fibrosis (CF) is well documented. Aspergillus fumigatus is the causative agent of ABPA, and Pseudomonas aeruginosa particularly the mucoid variety has been frequently isolated from the sputum of patients with CF. This study investigates the cellular and humoral immune response to both A fumigatus and P aeruginosa antigens in patients with CF and ABPA (CF/ABPA), CF only, and healthy controls. The A fumigatus and P aeruginosa antigen specific IgE and IgG in sera and peripheral blood mononuclear cell culture supernatants (PBMC sups), lymphoproliferation to antigens, and leukotriene B4 (LTB4) were measured. Results indicate significant elevated levels of A fumigatus specific IgG (A fumigatus-IgG) and Paeruginosa-IgE in serum. Significant Paeruginosa-IgG was measured in PBMC sups. The concanavalin A nonbinding A fumigatus antigen, previously shown to induce specific T-cell responses in vitro in patients with ABPA, elicited significant lymphoproliferative response in a greater proportion of patients with CF/ABPA and not in CF or controls, underlining the importance of this antigen in the diagnosis of ABPA. In contrast, a greater proportion of the CF group responded to P aeruginosa antigens compared with the controls and CF/ABPA. Hence, the CF and CF/ABPA groups respond to both P aeruginosa and A fumigatus antigens with the former group responding strongly to P aeruginosa and the latter to A fumigatus antigens.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7774329     DOI: 10.1378/chest.106.2.513

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  The first report on immunoglobulins A, E, G and M levels in cystic fibrosis patients in Saudi Arabia.

Authors:  Hani Alothaid; Hanaa Banjar; Fatuma M Kebir; Abeer Alharbi; Ghada Bin-Zuman
Journal:  Saudi J Biol Sci       Date:  2020-06-01       Impact factor: 4.219

Review 2.  Allergic bronchopulmonary aspergillosis.

Authors:  Richard B Moss
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

3.  Immunological characterization of Asp f 2, a major allergen from Aspergillus fumigatus associated with allergic bronchopulmonary aspergillosis.

Authors:  B Banerjee; P A Greenberger; J N Fink; V P Kurup
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

4.  Antibodies generated against conserved antigens expressed by bacteria and allergen-bearing fungi suppress airway disease.

Authors:  Nicholas W Kin; Emily K Stefanov; Brian L P Dizon; John F Kearney
Journal:  J Immunol       Date:  2012-07-25       Impact factor: 5.422

5.  Th2 allergic immune response to inhaled fungal antigens is modulated by TLR-4-independent bacterial products.

Authors:  Jenna B Allard; Lisa Rinaldi; Matthew J Wargo; Gilman Allen; Shizuo Akira; Satoshi Uematsu; Matthew E Poynter; Deborah A Hogan; Mercedes Rincon; Laurie A Whittaker
Journal:  Eur J Immunol       Date:  2009-03       Impact factor: 5.532

6.  Specific antibodies to recombinant allergens of Aspergillus fumigatus in cystic fibrosis patients with ABPA.

Authors:  Viswanath P Kurup; Alan P Knutsen; Richard B Moss; Naveen K Bansal
Journal:  Clin Mol Allergy       Date:  2006-07-21

7.  Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study.

Authors:  Shawn D Aaron; Katherine L Vandemheen; Andreas Freitag; Linda Pedder; William Cameron; Annick Lavoie; Nigel Paterson; Pearce Wilcox; Harvey Rabin; Elizabeth Tullis; Nancy Morrison; Felix Ratjen
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.